Nanoparticles Containing Quinoa Oil (Chenopodium quinoa Willd.): Toxicity Evaluation and Simulated Gastrointestinal Digestion.
Quinoa oil; Fatty acids; Nanoencapsulation; Cell viability; Simulated in vitro digestion.
Quinoa is a pseudocereal with high nutritional and bioactive potential, standing out for its high protein content, as well as vitamins, minerals, and phenolic compounds. The oil extracted from this seed presents significant amounts of unsaturated fatty acids and vitamin E, making it a product of functional interest. In this scenario, the nanoencapsulation of lipophilic compounds is a promising strategy to enable their solubilization in an aqueous matrix, preserve the integrity of bioactive compounds, increase bioavailability, and enhance the bioactive properties of the oil. Therefore, the objective of this work was to evaluate the cytotoxicity and simulated gastrointestinal digestion of nanoparticles containing quinoa oil. For this purpose, porcine gelatin (GS) and whey protein (WP) were used as encapsulating agents, associated with Tween 20 as a surfactant, aiming at the production of two nanoformulations through the oil/water emulsification technique: OG (quinoa oil + porcine gelatin) and OPG (quinoa oil + gelatin and whey protein). The nanoparticles were characterized in terms of morphology, diameter and chemical interactions (SEM, DLS and FTIR), evaluated for encapsulation efficiency, in vitro cytotoxicity (cell lines: CHO-K1, HeLa, 3T3 and A549) and in vivo (Caenorhabditis elegans), in addition to simulated in vitro gastrointestinal digestion. SEM characterization revealed particles with a physical size of 200 nm and a smooth, crack-free surface, with a spherical shape and diameters of 151.0 ± 44.51 and 198.3 ± 1.00 nm, respectively for OG and OPG. FTIR analysis indicated the attenuation of the oil's vibrational bands as well as the shifting of protein bands, attesting to chemical interactions between the encapsulating agents and the oil. Encapsulation efficiency was 92.69% ± 5.461 for the OG nanoformulation and 97.88% ± 0.065 for the OPG. Cytotoxicity analysis revealed that the oil did not exhibit cytotoxic effects on CHO-K1, HeLa, 3T3, and A549 cells (> 95%) after 24 hours, and specific cytotoxicity in 3T3 cells (67%) after 72 hours. Regarding nanoparticles, OG did not show cytotoxic potential at high concentrations (90%) even after 72 hours, and OPG demonstrated cytotoxicity to 3T3 and A549 cells and an absence of cytotoxic effect on CHO-K1 and HeLa cell lines. Furthermore, the in vivo toxicity of quinoa oil to Caenorhabditis elegans was evaluated using the egg hatching assay, showing no statistical difference between the control group and the tested concentrations (p > 0.05). In vitro gastrointestinal release demonstrated the absence of fatty acids in both formulations during the oral phase. The OG sample showed greater gastric release, with 41.650% ± 14.463 of linoleic acid and 33.360% ± 0.000 of oleic acid released, while the OPG sample performed better in the intestinal phase, with 64.160% ± 0.730 of linoleic acid released and 21.310% ± 2.810 of oleic acid released. Thus, nanoencapsulation of quinoa oil proved to be a strategy that optimizes the bioactive properties of the oil, expanding its possibilities for industrial application